Adalimumab in Psoriatic Arthritis

Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2012-07, Vol.39, p.77-81
Main Authors: SALVARANI, Carlo, PIPITONE, Nicolò, CATANOSO, Mariagrazia, CHIAROLANZA, Ilaria, BOIARDI, Luigi, CARUSO, Andrea, PAZZOLA, Giulia, MACCHIONI, Pierluigi, DI LERNIA, Vito, ALBERTINI, Giuseppe
Format: Article
Language:English
Subjects:
Adalimumab
Anti-Inflammatory Agents - adverse effects
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Arthritis, Psoriatic - diagnosis
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - immunology
Biological and medical sciences
Dermatology
Diseases of the osteoarticular system
Evidence-Based Medicine
Humans
Immunomodulators
Inflammatory joint diseases
Medical sciences
Pharmacology. Drug treatments
Psoriasis. Parapsoriasis. Lichen
Severity of Illness Index
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis. ADA significantly inhibited structural changes on radiographs, lessened disability, and improved quality of life in patients with active PsA. One study showed the efficacy of 24-week ADA therapy on bone marrow edema and erosions, as measured by magnetic resonance imaging. The clinical and radiographic efficacy of ADA demonstrated during short-term treatment was sustained during longterm treatment. ADA was generally well tolerated and its safety profile was similar to that reported in studies of ADA in rheumatoid arthritis. Overall, ADA has a favorable risk-benefit profile in PsA. The combination of ADA and cyclosporine seems to be more effective than ADA monotherapy in patients with active PsA and inadequate response to methotrexate; however, this observation must be confirmed in RCT.
ISSN:0315-162X
0380-0903
1499-2752
DOI:10.3899/jrheum.120251